Revenue 37% YoY, margins flat; $400M FY28 target credible but execution-heavy

Revenue ₹449Cr (4,490M) +37.2% YoY verified. EBITDA claimed 27.4% vs OPM delivered 26.5%; 3.5% variance likely depreciation add-back, immaterial.

MD specific, customer day-one launches confirmed. Market size <2K to 160K pens/month YoY growth validates scale. Not independently verified but consistent with disclosed customer wins.

Q1 annualized run-rate ~₹1,800Cr (vs $400M ≈ ₹3,300Cr). Requires 83% CAGR. Order book claimed 'yes' but not quantified; analyst acceptance suggests credibility but unverified.

Revenue-wise full, EBITDA-wise not due to upfronted capex-related opex across all lines. Transparent disclosure; expected to resolve as lines load.

Under Strides was captive IP-led. Now CDMO services; European tech transfers underway. Capacity 2.4B units, 12-15 months to full utilization vs prior assumption faster ramp.

Formycon (large biosimilar player) announced this quarter. RFP funnel 4x YoY. Prior calls mentioned pipeline potential; now concrete wins, but revenue FY29+.

Lines 2, 3 scheduled Q2 and end-FY27. Line 4 in FY28. Clear timeline communicated, no change to $400M FY28 target.

Under Strides captive, now CDMO services. European players have capacity challenges. Tech transfers take time; expect 12-15 months full utilization. Initiating greenfield expansion.

No. Diverse customer base. Pulling demand into Q1. Adding capacity starting Q2. All current capacity full.

Yes. Multiple pillars: DDC (3-on-3 Canada, 40% India), biologics (4x RFP funnel), soft gel (being filled), injectables (new capabilities).

Lines fully fungible; customers serviced from both. Batch 200L→500L; most geographies approve quickly, market-by-market basis.

Yes, EBITDA trajectory continues upward. Biologics commercialize FY29+. Soft gel, injectables ramping. Europe/US DDC opens FY29+.

Formycon (large biosimilar player) announced. Animal health win prior quarter. Long-term sticky. Commercialization FY29+, currently MSA. Will expand mammalian/microbial capacity.

DDC, injectables at peak. Soft gel in tech transfer (12-15 months to full). Pre-filled syringes available for new customers.

$100M total, 80% committed (mostly DDC). Biologics capex 'significantly lower' than DDC. No FY27/FY28 split given.

Supply constraint, not demand. India: <2K to 150K-160K pens/month YoY. Still constrained. All customer forecasts robust.

Clear demand visibility. Line 2 Q2 FY27, line 3 by year-end. No major risks cited.

Expected to launch current quarter. Only one other supplier. Demonstrates capability. Small market, no significant near-term contribution.

Revenue yes (full per-day realization). EBITDA no; opex upfronted across all lines. Optimal EBITDA when all lines live.

Freight delays (Cape routing), container constraints. Impact muted: all ex-works (customers absorb). US tariff: too early, many admin reversals, no long-term harm expected.

Capacity additions (line 2 Q2, line 3 year-end). Sequential revenue/EBITDA improvement. Operating leverage kicking in.

Reaffirmed from prior calls. Requires 83% annualized CAGR from ₹1,800Cr Q1 run-rate. Order book claimed visible; execution risk on 3 line ramps, soft gel CDMO ramp, biologics commercialization.

Reaffirmed. Requires +1350bps from Q1 26.5% OPM. Relies on revenue growth (fixed cost dilution) and operating leverage. Q1 margin flat despite 37% growth due to upfronted capex opex.

Mostly DDC lines. Additional biologics capex 'significantly lower' than DDC. No FY27/FY28 allocation detail provided.

Lines 2, 3 must come online on schedule (Q2, Q3-Q4 FY27). Line 4 in FY28. Batch size increases (200L→500L) require market-by-market regulatory approvals. Any delay cascades FY28 guidance.

Capacity 2.4B units; currently in tech transfer phase. Timeline 12-15 months to full utilization. European customers still ramping; delays here squeeze capacity for new customer wins.

Biologics key to long-term growth beyond FY28. Currently all MSA revenues (development stage). Formycon, animal health contracts assume FY29 commercial launch. Any delay (regulatory approvals, manufacturing scale-up, market adoption) pushes revenue.

Named customers: Dr. Reddy's (implied major), Apotex (Canada), Formycon (biosimilars). Others unnamed. Loss of any top customer materially impacts guidance. Concentration not quantified.

Current momentum driven by supply scarcity and latent demand boom (India <2K→160K pens/month YoY). If supply normalizes or demand saturates, growth slows. Generic price compression likely as market matures.